Research Tracker›Biomarker Atlas›Marker Pages›Lyme arthritis RF/anti-CCP

Lyme arthritis RF/anti-CCP: biomarker evidence

Lyme arthritis RF/anti-CCP appears in 1 entry of the OSMF biomarker atlas, covering Lyme Disease. Across those entries it is reduced in 1. It is currently reported in a single condition in this atlas; cross-condition comparison will be added as the dataset grows. Each row below links to a page with the comparison group, associated symptoms, test details and primary citation.

Lyme Disease

Where Lyme arthritis RF/anti-CCP is reported

Also listed as: Rheumatoid panel

ConditionDirectionCompared againstAssociated symptomsSource
Lyme Disease↓ reducedRA patientsNegative — helps distinguish RALantos et al. 2021

Frequently asked questions

In which conditions is Lyme arthritis RF/anti-CCP altered?

In the OSMF atlas Lyme arthritis RF/anti-CCP is reported in Lyme Disease. It is reduced in 1 across 1 entries.

Is there a standard clinical test for Lyme arthritis RF/anti-CCP?

The atlas entries for Lyme arthritis RF/anti-CCP do not carry a LOINC code, which usually means the marker was measured with research assays or study-specific methods rather than a routine clinical panel.

Is one abnormal Lyme arthritis RF/anti-CCP result diagnostic?

No single biomarker result is diagnostic of any of these conditions. Findings reflect group averages from published cohorts with substantial overlap between patients and controls.

Cite this page

Open Source Medicine Foundation. (2026). Lyme arthritis RF/anti-CCP across conditions: biomarker evidence. OSMF Research Tracker. Retrieved October 7, 2026, from https://research.opensourcemed.info/biomarkers/markers/lyme-arthritis-rf-anti-ccp.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-06-29 · Browse: Biomarker Index · All marker pages · Biomarker Atlas

Disclaimer: Educational synthesis of peer-reviewed research; not medical advice. Findings are group-level and vary with study design. Discuss any result with a qualified clinician.